Evidence map›Paper›PMID 30911669›Full record

ArticlePleura and peritoneum2018

Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) as an outpatient procedure.

Martin Graversen, Lars Lundell, Claus Fristrup, Per Pfeiffer, Michael B Mortensen

2 registry-linked trialsOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pleura and peritoneum, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03287375 phase2completednot on this map

Treatment of Peritoneal Carcinomatosis With Pressurized IntraPeritoneal Aerosol - The PIPAC-OPC2 Trial

TypeinterventionalSponsorMichael Bau MortensenRan2016 to 2022Enrolled143ConditionsPeritoneum, Carcinomatosis, Peritoneal Neoplasms, Peritoneal MetastasesArmsPIPAC
NCT04047004 phase1completednot on this mapstarted 2020, after this paper: background citation

Adjuvant Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) During Laparoscopic Resection in High-risk Gastric Cancer Patients: A Multicentre Phase-I Study (the PIPAC-OPC4 Study)

TypeinterventionalSponsorMichael Bau MortensenRan2020 to 2022Enrolled20ConditionsGastric Adenocarcinoma, Gastric CancerArmsDoxorubicin, Cisplatin
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. PIPAC for Gastrointestinal Malignancies.Journal of clinical medicine · 2023
    Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Martin GraversenOdense PIPAC Center & Odense Pancreas Center (OPAC), Odense Patient data explorative Network (OPEN), Odense University Hospital, Odense, Denmark.
Lars LundellOdense PIPAC Center & Odense Pancreas Center (OPAC), Odense Patient data explorative Network (OPEN), Odense University Hospital, Odense, Denmark.
Claus FristrupOdense PIPAC Center & Odense Pancreas Center (OPAC), Odense Patient data explorative Network (OPEN), Odense University Hospital, Odense, Denmark.
Per PfeifferOdense PIPAC Center & Odense Pancreas Center (OPAC), Odense Patient data explorative Network (OPEN), Odense University Hospital, Odense, Denmark.
Michael B MortensenOdense PIPAC Center & Odense Pancreas Center (OPAC), Odense Patient data explorative Network (OPEN), Odense University Hospital, Odense, Denmark.
Odense University Hospital · DKKarolinska Institutet · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) is a drug-delivery method for patients with peritoneal metastasis (PM). The study objective was to investigate whether PIPAC is possible in an outpatient setting.

methodsData was extracted from the prospective PIPAC-OPC2 study (ClinicalTrials.gov NCT03287375). Patients with PM were treated by cisplatin and doxorubicin (PIPAC C/D), except patients with colorectal PM, who were treated by oxaliplatin (PIPAC OX). Patients were evaluated concerning the suitability for carrying out the PIPAC procedure in an out- patient setting. The preconditions for outpatient surgery were that the patient should be (1) freely mobilized, (2) adequately pain-relieved, (3) have untroubled urination and (4) without anxiety or discomfort caused by leaving the hospital.

resultsDuring the study period, 106 PIPAC procedures (79 PIPAC C/D, 27 PIPAC OX) were performed in 41 patients with gastrointestinal or ovarian PM. Ninety percent (37/41) of the patients were pretreated with systemic chemotherapy. Eight patients (20%) received bidirectional chemotherapy. Twenty-four percent (10/41) of the first PIPAC procedures were completed in an outpatient setting, which increased to 65% (13/20) in PIPAC no 3 (p=0.008). In the PIPAC C/D cohort, 28% and 80% of the PIPACs were performed in the outpatient setting at PIPAC 1 and 3 respectively, contrasting to only 11% and 20% in the PIPAC OX group. No readmissions after outpatient care. Postoperative morphine administration was more frequent in the PIPAC OX group.

conclusionsThe PIPAC procedure can be performed in an outpatient setting. The critical component for success is pain control.

Indexed as

complicationsintraperitoneal chemotherapyoutpatient procedureperitoneal metastasisPIPAC

Identifiers

PMID30911669
PMCPMC6405001
OpenAlexW2902772726

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.